1. Home
  2. QSI vs NYXH Comparison

QSI vs NYXH Comparison

Compare QSI & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quantum-Si Incorporated

QSI

Quantum-Si Incorporated

HOLD

Current Price

$0.71

Market Cap

161.8M

Sector

Health Care

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$3.31

Market Cap

152.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QSI
NYXH
Founded
2013
2009
Country
United States
Belgium
Employees
145
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
161.8M
152.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
QSI
NYXH
Price
$0.71
$3.31
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$1.00
$11.25
AVG Volume (30 Days)
2.9M
55.8K
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$214.32
Revenue Next Year
$618.07
$124.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.72
$2.76
52 Week High
$3.10
$8.64

Technical Indicators

Market Signals
Indicator
QSI
NYXH
Relative Strength Index (RSI) 31.47 45.83
Support Level N/A $2.76
Resistance Level $1.11 $3.32
Average True Range (ATR) 0.05 0.18
MACD -0.01 0.09
Stochastic Oscillator 8.88 59.66

Price Performance

Historical Comparison
QSI
NYXH

About QSI Quantum-Si Incorporated

Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: